BTV100
Ocular Dry Eye Disease
Pre-clinicalActive
Key Facts
About BioTheraVision
BioTheraVision is a pre-clinical, private biotech based in Chicago, IL, leveraging a drug repurposing platform for ophthalmology. The company's pipeline includes BTV100 for dry eye disease and BT300 for post-ocular surgery inflammation, both in pre-clinical development. With six U.S. patents pending and a team experienced in ocular drug development, BTV is positioned to advance novel treatments in large, underserved ophthalmic markets. The company is currently pre-revenue and focused on validating its candidates through the pre-clinical stage.
View full company profile